# To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

> **NCT00398099** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (—)

## Conditions studied

- Infection
- Pneumonia
- Urinary Tract Infection

## Interventions

- **DRUG:** MK0826, ertapenem sodium / Duration of Treatment: 14 Days

## Key facts

- **NCT ID:** NCT00398099
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 30 (—)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398099, "To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00398099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*